The metabolism and pharmacokinetics of phospho‐sulindac (OXT‐328) and the effect of difluoromethylornithine
@article{Xie2012TheMA, title={The metabolism and pharmacokinetics of phospho‐sulindac (OXT‐328) and the effect of difluoromethylornithine}, author={Gang Xie and Ting Nie and G G Mackenzie and Y Sun and L. Huang and Nengtai Ouyang and Ninche Alston and C. Zhu and Onika T. Murray and Panayiotis Constantinides and Levy Kopelovich and Basil Rigas}, journal={British Journal of Pharmacology}, year={2012}, volume={165} }
BACKGROUND AND PURPOSE Phospho‐sulindac (PS; OXT‐328) prevents colon cancer in mice, especially when combined with difluoromethylornithine (DFMO). Here, we explored its metabolism and pharmacokinetics.
21 Citations
Regioselective oxidation of phospho‐NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety
- Biology, MedicineBritish journal of pharmacology
- 2012
Phospho‐ibuprofen and phospho‐sulindac metabolism by major human cytochrome P450s (CYPs) and flavin monooxygenases (FMOs) is investigated.
The in vitro metabolism of phospho-sulindac amide, a novel potential anticancer agent.
- Biology, ChemistryBiochemical pharmacology
- 2014
The ocular pharmacokinetics and biodistribution of phospho‐sulindac (OXT‐328) formulated in nanoparticles: Enhanced and targeted tissue drug delivery
- Biology, MedicineInternational journal of pharmaceutics
- 2019
Aerosol Administration of Phospho-Sulindac Inhibits Lung Tumorigenesis
- Biology, ChemistryMolecular Cancer Therapeutics
- 2013
It is found that administration by inhalation delivered high levels of phospho-sulindac to the lungs and minimized its hydrolysis to less active metabolites and was highly effective in inhibiting lung tumorigenesis and significantly improved the survival of mice bearing orthotopic A549 xenografts.
Phospho-Sulindac (OXT-328) Inhibits the Growth of Human Lung Cancer Xenografts in Mice: Enhanced Efficacy and Mitochondria Targeting by its Formulation in Solid Lipid Nanoparticles
- Biology, ChemistryPharmaceutical Research
- 2012
The results show that SLN-PS is efficacious in suppressing the growth of lung cancer and merits further evaluation, suggesting that it specifically induced oxidative stress in tumors.
Development of oseltamivir phosphonate congeners as anti-influenza agents.
- Biology, ChemistryJournal of medicinal chemistry
- 2012
Oseltamivir phosphonic acid, its mono methyl ester, guanidino-tamiphosphor, and its monoethyl ester are potent inhibitors of influenza neuraminidases that inhibit the replication of influenza viruses at low nanomolar to picomolar levels, and significantly protect mice from infection with lethal doses of influenza virus when orally administered with 1 mg/kg or higher doses.
Carboxylesterases 1 and 2 Hydrolyze Phospho-Nonsteroidal Anti-Inflammatory Drugs: Relevance to Their Pharmacological Activity
- Biology, ChemistryJournal of Pharmacology and Experimental Therapeutics
- 2012
Results show that carboxylesterase mediates that metabolic inactivation of phospho-NSAIDs, and the inhibition of carboxyleterases improves the efficacy of phosphate- NSAIDs in vitro and in vivo.
Curcumin enhances the lung cancer chemopreventive efficacy of phospho-sulindac by improving its pharmacokinetics
- Biology, ChemistryInternational journal of oncology
- 2013
Results show that curcumin substantially improves the pharmacokinetics of PS leading to synergistic inhibition of the growth of human lung cancer xenografts, representing a promising drug combination.
Recent Developments in Chimeric NSAIDs as Safer Anti‐Inflammatory Agents
- Medicine, BiologyMedicinal research reviews
- 2015
This review deals with approaches and strategies that have been employed in the last two decades and are being used currently in the design and development of safer NSAIDs.
NSAIDs: Old Acquaintance in the Pipeline for Cancer Treatment and Prevention─Structural Modulation, Mechanisms of Action, and Bright Future.
- BiologyJournal of medicinal chemistry
- 2021
The most recent outcomes for the treatment and prevention of different types of cancers for several NSAIDs alone or in combination with current chemotherapeutic drugs are reported and an extensive review of the most promising structural modifications is reported.
References
SHOWING 1-10 OF 51 REFERENCES
Phospho-Sulindac (OXT-328) Combined with Difluoromethylornithine Prevents Colon Cancer in Mice
- Medicine, BiologyCancer Prevention Research
- 2011
P-S/DFMO is an efficacious drug combination for colon cancer prevention and also show the safety of P-S, which may overcome the limiting side effects of conventional sulindac.
Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice.
- Biology, MedicineGastroenterology
- 2010
BACKGROUND & AIMS
Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective cancer chemopreventive agents. However, chronic administration of NSAIDs is associated with significant side effects,…
Mitochondrial uncoupling by the sulindac metabolite, sulindac sulfide.
- Biology, MedicineBasic & clinical pharmacology & toxicology
- 2006
Sulindac sulfide caused mitochondrial uncoupling, released preaccumulated Ca2+ from the organelle, and decreased Hep-G2 cell viability in apparent association with cell ATP depletion resulting from mitochondrial uncOUpling-associated membrane potential dissipation.
The novel phospho‐non‐steroidal anti‐inflammatory drugs, OXT‐328, MDC‐22 and MDC‐917, inhibit adjuvant‐induced arthritis in rats
- MedicineBritish journal of pharmacology
- 2011
Three novel modified NSAIDs are evaluated for the anti‐inflammatory efficacy and safety in rheumatoid arthritis: phospho‐aspirin,ospho‐ibuprofen and phospho-sulindac.
The Role of Cyclooxygenase Inhibition in the Antineoplastic Effects of Nonsteroidal Antiinflammatory Drugs (Nsaids)
- MedicineThe Journal of experimental medicine
- 1999
According to WHO statistics, in 1996 875,000 new cases of colorectal cancer were diagnosed and 495,000 deaths were attributed to it worldwide ([1][1]). It is the third most common cause of cancer…
Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations
- Biology, MedicineCellular and Molecular Life Sciences
- 2009
Mechanistic analysis demonstrated that SSi directly suppresses 5-LO with an IC50 of 20 μM, which may provide a novel molecular basis to explain the COX-independent pharmacological effects of sulindac under therapy.
Phospho-Ibuprofen (MDC-917) Is a Novel Agent against Colon Cancer: Efficacy, Metabolism, and Pharmacokinetics in Mouse Models
- Biology, ChemistryJournal of Pharmacology and Experimental Therapeutics
- 2011
The results provide a pharmacological basis to explain, at least in part, the anticancer efficacy and safety of this promising compound and indicate that PI merits further evaluation as an anticancer agent.
Synthesis and biological identification of the acyl glucuronide of the antiinflammatory drug ML-3000
- Chemistry
- 1997
In Vitro Metabolism of Nitric Oxide-Donating Aspirin: The Effect of Positional Isomerism
- Chemistry, BiologyJournal of Pharmacology and Experimental Therapeutics
- 2005
The three positional isomers of NO-ASA differ in their metabolism and these differences correlate with their differential effects on cancer cell growth, underscoring the importance of positional isomerism in modulating drug effects.
Effect of Carboxylesterase Inhibition on the Anti-Tumour Effects of Irinotecan
- MedicineThe Journal of international medical research
- 2005
A direct correlation was found between the dose of administered BNPP and the growth rate of the tumour, demonstrating that the anti-tumour effects of CPT-11 were related to the CE concentration.